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Abstract
Dry eye affects 35% of population, and it is a cause of chronic pain and discomfort. The 
conventional treatment with lubricants is often not sufficient in moderate to severe cases, 
which can lead to complications such as keratopathies, corneal opacities, ocular perfora-
tions, and visual loss. Platelet-rich plasma (PRP) eyedrops have already been used in 
ocular surface diseases due to their role in epithelialization and the presence of growth 
factors and vitamins that are similar to human tears. We intend to make a literature 
review of the use of platelet-rich plasma in dry eye disease, and present the results of 
a 13 case series, of diabetic severe dry eye patients that used this alternative treatment.
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1. Introduction
In this chapter we will cover a brief literature review on the use of platelet concentrate in dry 
eye, especially in moderate and severe cases that are generally refractory to conventional treat-
ment, and we will cite some results of its use in other areas of medicine by several authors.
2. Dry eye: definition and classification
The tear has several important functions to the ocular surface, such as lubrification, transport of 
oxygen, carbon dioxide and other metabolites, immunological actions, and maintenance a stable 
corneal surface, among others. It is rich in immunoglobulins, growth factors, and vitamin A. It 
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is separated in three layers: the lipid layer, which protects the tear against evaporation and is 
secreted by Moll, Meibomian, and Zeiss glands [1]; the mucin layer produced by Manz glands, 
Henle crypts, and corneal and conjunctival cells—this one stays between the hydrophobic ocu-
lar surface and the hydrophilic tear film [2]; and the last and the most prevalent layer, the aque-
ous layer, produced by Wolfring and Krause glands [3].
The most recent definition of dry eye is that it is a multifactorial disease of the tears and 
ocular surface, which is accompanied by ocular symptoms, in which tear film instability and 
hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities 
play etiological roles [4]. The inflammation of the ocular surface can be both the cause and the 
consequence of dry eye: dysfunction of the lacrimal glands alters the tear composition, lead-
ing to hyperosmolarity that stimulates more inflammation [5], and another factor recognized 
in dry eye pathogenesis is oxidative stress [6].
There are several risk factors for dry eye, all of them are controversial. These are female sex, 
menopause therapy, omega-3 deficiency, refractive surgeries; use of some medications as antihis-
taminic drugs, antihypertensive drugs, diuretics, antidepressants, and others; hepatitis C; radia-
tion therapy; Asian race; HIV and HTLV infection; chemotherapy; isotretinoic acid use; large 
facetectomy incisions; low humidity environments; ovarian dysfunction; and sarcoidosis [7].
This disease is actually classified into two primary categories: these are tear-deficient and 
evaporative categories. The tear-deficient dry eye group generally can be due to Sjogren’s syn-
drome or non-Sjogren’s syndrome. Sjogren’s syndrome is an exocrinopathy in which lacrimal 
secretion deficiency occurs due to an autoimmune process that affects the lacrimal glands, sal-
ivary glands, and other organs of the body [8]. Non-Sjogren’s syndrome is caused by lacrimal 
diseases or lacrimal obstruction and by reflex alterations, without autoimmune factor role. 
Some causes are age-related dry eye, congenital alacrima, familial dysautonomia, sarcoidosis, 
lymphoma, AIDS (acquired immunodeficiency disease syndrome), gland denervation, lacri-
mal obstruction as in pemphigus, trigeminal injury, diabetes, neurotrophic keratopathy, use 
of contact lenses, and motor reflex block due to VII pair injury [9, 10]. The evaporative causes 
of dry eye disease are due to oil deficit, lid changes, use of contact lenses, or ocular surface 
diseases, as allergic conjunctivitis, and some of the iatrogenic dry eye that occurs after the use 
of systemic or topical medications or after surgeries or nonsurgical procedures [8, 11].
Dry eye can be also classified according to severity. One of the schemes is proposed by Delphi 
Panel [8, 12]. This classification in grades 1–4 (mild to severe) is based on the frequency or 
intensity of the dry eye symptoms and discomfort, the blurred vision and visual symptoms, 
conjunctival injection or redness, conjunctival staining, corneal staining, changes in the cor-
nea and tear as in ocular surface, alterations in the glands and lids, tear film break-up time 
(TFBUT), and Schirmer’s test values.
3. Epidemiology
Dry eye disease affects from 5 to 50% of population; this discrepancy is probably observed 
due to the absence of a consensus on the diagnosis of dry eye and the lack of standardization 
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in its classification [13]. It is more frequently in women [14], probably because of the hormone 
effects in the ocular surface and eye glands [4].
It is more common in Asia and Europe, with only one study showing the prevalence in South 
of Equator [4], and it seems to be also more frequent in older people, possibly because of the 
aging alterations in the lids, glands, ocular surface, and adnexal tissue [15].
4. Diagnosis and treatment
Diagnosis is controversial, and literature shows the lack of correlation between some objective 
tests and symptoms; this is probably due to the difficulty in understanding dry eye patho-
physiology [16].
There are some guidelines in this theme, and one of them is the American Academy of 
Ophthalmology that relates that dry eye diagnosis is obtained after a clinical approach that 
include asking the patient about exposition to dry eye risk factors and the most common 
symptoms and signs like redness, itching, photophobia, dryness, foreign body sensation, or 
pain. It is also important to ask the patient about the exposition to some kind of pollutant, if 
he is a smoker, if he has any systemic disease (like dermatological, allergic, or rheumatic dis-
eases), checking the hygiene of eyelashes and eyelids, use of medications, eyedrop use, pre-
vious ocular surgeries [17], and use of a screening questionnaire as the OSDI (Ocular Surface 
Disease Index) [18]. The clinical history is followed by a complete ophthalmological exam, 
including evaluating the eyelids, skin, nerves, visual acuity, and biomicroscopy, and some 
specific tests like tear breakup time, tear film osmolarity determination, and ocular surface 
staining with fluorescein lissamine green [4]. The assessment of the tear meniscus (less than 
0.35 mm is abnormal) can be performed, verifying if the blink rate is decreased and evaluate 
the quality of the tear (if there are mucus and debris) and corneal topography [3].
Management of dry eye disease will depend on the cause of this condition and its severity. 
There is currently no cure for dry eye, and any causal factors that are amenable to treatment 
should be treated. It includes modifications of the environment; suspension of topical or sys-
temic medications, associated with worsening when possible; artificial tear lubrification; and 
eyelid hygiene [19].
Generally, the conventional treatment is the lubricants, but it does not resolve all the cases. There 
are a wide variety of artificial tears, like 1% sodium hyaluronate, hypotonic solutions,  those that 
contains lipids or substances with bioadhesive properties and formulas that have substances that 
protects the cell’s stress; but none of them has the natural tear properties [20, 21].
Other therapies are topical cyclosporine and corticosteroids [22], but these have some disad-
vantages such as eye irritation and ocular pressure elevation and cataract, respectively [23, 24]. 
In moderate cases we can also use systemic supplements with omega-3 and linoleic acids and 
the increased consumption of water, lacrimal occlusion, and glasses use. In severe dry eye, 
in addition to all these treatments, we can take another measure like systemic cholinergic 
agonists, systemic anti-inflammatory agents, mucolytic agents, contact lenses, correction of 
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palpebral alterations, permanent lacrimal punctal occlusion, tarsorrhaphy, and, finally, the 
autologous serum tears [17].
The Ebers Papyrus 1534 BC is the first reference in the history of a blood derivative in the eye. 
In 1975, Ralph et al. used it in dry eye [25]. Fox et al. and later Tsubota related the use of autol-
ogous serum as an alternative treatment of severe dry eye cases [26, 27]. During many years 
of study, fetal bovine serum, allogenic serum, and umbilical cord serum have been used; 
however, they are heterologous, the risks of infections or allergic reactions are increased, and 
their use is not possible in any center [28]. It does not have preservative, and it is rich in vita-
mins, fibronectin, growth factors, and cytokines and has biomechanical properties similar 
to natural tear film, and they do not have preservative which is common in artificial tears 
[29]. Epidermal growth factors and vitamin A are important for proliferation, differentiation, 
and maturation of the ocular surface epithelium [30]. Fibroblast growth factor-beta is also 
involved in epithelial healing, fibronectin promotes cell migration, albumin has antiapoptopic 
activity, alpha-2-macroglobulin has anti-collagenase action, platelet-derived growth factor 
promotes hepatocytes growth factor, and substance P and insulin-like growth factor aid in 
the migration and adhesion of epithelium to the stroma [31]. The serum also maintains intra-
cellular ATP at acceptable levels and cell membrane integrity [32–35].
Some authors related the use of autologous serum drops in dry eye with some promisor 
results [35, 36].
Kojima et al. in 2005 described increased TFBUT in treated group comparing to control group 
(using artificial tears) [37]. Lee and Chen studied the use of autologous serum in 23 patients 
by 18 months and found improvements in symptoms and corneal staining pattern in approxi-
mately 75% of patients [38].
Other indications for the use of autologous serum have been the epithelial defects [39], graft-
versus-host disease [40], neurotrophic keratopathy [41], trabeculectomy ampoules [42], after 
refractive surgery [43, 44], Mooren’s ulcer [45], and other keratitis [46].
Tananuvat et al., in a randomized prospective study, found that control eyes had improve-
ment in symptoms, signs, and rose bengal staining compared with the baseline. However, some 
advantages neither Schirmer’s test results nor tear breakup time improved in treated group [34].
Urzua et al. described in a double-blind crossover clinical trial 12 severe dry eye syndrome 
patients in which autologous serum treatment showed a statistically significant higher OSDI 
decrease (50%) versus conventional treatment (22%). There were no significant changes in 
objective parameters (Oxford corneal staining and TBUT) [47]. A review to evaluate autolo-
gous serum efficacy compared to lubricants, in dry eye disease, concluded that there is a great 
heterogeneity considering the preparation and storage of the eyedrops, as well as the adequate 
use of this therapy, and that new studies that standardize these items would be necessary [19].
Another alternative, platelet-rich plasma (PRP), can be used in severe dry eye. It is prepared 
in double centrifugation of total plasma. Some of the important growth factors this hemoderi-
vate has are platelet-derived angiogenesis factor, platelet-derived epithelial growth factor, 
and platelet factor 4 [48].
The epidermal growth factor accelerates the healing process and epithelial migration in the 
cornea, besides stimulating the DNA synthesis of the epithelial cells, and is also associated 
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with the production of mucin 1 by some conjunctival cells. Transforming growth factor b1 
(TGF-b1) has an increased levels in the epithelium during corneal stromal repair processes; 
it stimulates the production of collagen, fibronectin, and proteoglycans and together with 
the platelet-derived growth factor (PDGF) has an important anti-inflammatory action [49]. 
Vitamin A is one of the major epitheliotropic factors in autologous serum; it is 100 times more 
concentrated than in natural tear and prevents squamous epithelial metaplasia [50].
Fibronectin is an important protein to corneal reepithelization, promoting healing and phago-
cytosis [51]. Annexin A5 has been investigated as an alternative to fibronectin eyedrops. It 
interacts with some integrins and stimulates the secretion of plasminogen activator-type uro-
kinase, whose expression is increased in epithelial defects. Albumin is one of the most impor-
tant proteins in the blood. It reduces the natural degradation of cytokines and growth factors 
in areas of tissue injury and shows antiapoptopic activity [39, 52, 53]. Alpha-2-macroglobulin 
neutralizes proteolytic enzymes. It is useful in ocular burns and marginal ulcers [32, 39]. 
Fibroblast growth factor-beta is a factor that promotes corneal healing, increasing cell prolif-
eration and motility [54].
The insulin-like growth factor helps epithelial cell migration [55]. Neural growth factor (NGF) 
is the most well-known neurotrophin. It restores the function of injured neurons and can be 
effective in trophic ulcers [56].
One of the PRP advantages is that it has not cytokines derived from leucocytes and monocytes, 
which are present in autologous serum and can be deleterious in patients with immune diseases 
[57]. PRP also regulates expression of several genes in the cellular differentiation improving 
biological activity of the corneal epithelial cells when compared with autologous serum [58].
The PRP protects the ocular surface from scar formation more than autologous serum, because 
of reduction of myofibroblasts. It has been observed in PRK where patients who had done this 
surgery has a decreased incidence of haze [59]. PRP causes reduction in inflammation by indi-
rect action, through the reduction of osmolarity, thus, diluting the pro-inflammatory factors 
existing in the ocular surface. This also occurs because of the presence of the growth factor-
rich plasma interleukin-1 receptor antagonist as well as the presence of metalloproteinase [60].
Platelets have a lot of important functions that are repairing tissue damage; coagulation pre-
vents blood loss, secreting proteins, cytokines, and other mediators; inducing tissue regenera-
tion by cell migration, proliferation, and angiogenesis, and preventing infections because of 
its antibiotic action. They also have an anti-inflammatory and analgesic action [61].
5. The use of PRP in medicine and odontology
Platelet-rich plasma has been used in several medical and dental areas. The platelet-rich 
plasma has approximately 1 million/ml platelets [62], and it has been used to the revitaliza-
tion of necrotic pulp teeth [63], in periodontitis [64], in revascularization of young teeth [65], 
and in other oral conditions [66].
Platelet-rich plasma has been used in orthopedic therapies like cartilage repair [67], also in 
bone regeneration, and in tendons, ligaments, and articular lesions [68].
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In dermatology, PRP has been used for wound healing of acne scars [69], vitiligo [70], venous 
ulcers [71], alopecia [72], skin rejuvenation [73], and some cases of lichen sclerosus [74].
In gynecology, there are studies where PRP had been used in cases of infertility [75], in uterine 
prolapse [76], in inducing endometrium proliferation [75], and in scars of cesarean sections [77].
It has also been used in otolaryngology [78], in urinary diseases [79], and in other medical 
specialties.
6. The use of PRP in ophthalmology
PRP has been reported in corneal ulcers [80–82], in chemical burns [83, 84], in restoration of 
lacrimal function [85], in blepharoplasties surgeries [86], in ocular surface syndrome after 
refractive surgeries [44], and in graft-versus-host disease [87].
In dry eye, there are few studies reporting the use of PRP. Alio et al., in 2007, evaluated 18 
symptomatic patients that used this treatment for 1 month and observed that symptoms 
of dry eye improved in 89% of patients, that conjunctival injection was present in 38.9% of 
patient, that 86% of the symptoms decreased, that lachrymal meniscus improved in 56% of 
the cases, and that corneal staining also decreased. In impression cytology increase in con-
junctival goblet cells was observed [88].
Ribeiro et al., had studied about diabetic dry eye patient. They evaluated 12 patients with 
grades 2–4 of severity [8, 12]; 41.67% had a reduction in Schirmer’s gradation, 58.33% had an 
increase in TFBUT (tear film breakup time), visual acuity improved in 41.66% of patients, and 
OSDI questionnaire score significantly improved in 100% of patient. The authors also found 
that before treatment, 91.67% had severe dry eye and after treatment, 50% were classified as 
normal, 25% as mild dry eye, 16.66% as moderate dry eye, and just one patient had instead a 
severe dry eye (Figures 1–5) [89].
Figure 1. Before and after treatment with PRP in patient with diabetic dry eye.
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Figure 2. Before and after treatment with PRP in patient with diabetic dry eye.
Figure 3. Before and after treatment with PRP in patient with diabetic dry eye.
Figure 4. Before and after treatment with PRP in patient with diabetic dry eye.
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Recently, in 2017, Alio reported a 368-patient prospective, interventional nonrandomized 
study, where moderate to severe dry eye was included. The results were as follows: Schirmer’s 
test value had a significant improvement, subjective symptoms had an improvement in 87.5% 
of patients, OSDI scores were statistically significant, 28.8% experienced an increase of one 
or more lines of vision, decrease in corneal fluorescein staining was observed in 76.1% of 
patients, and only one patient reported intolerance to the use of PRP due to discomfort at the 
time of instillation [90].
Another alternative that has been reported in dry eye treatment is the plasma rich in growth 
factors (PRGF). Lopez-Plandolit et al. observed that PRGF treatment was associated with 
improvement in score dry eye questionnaire values and as results from impression cytology. 
In 75% of patients, no further medication was required. But squamous metaplasia did not 
reduce significantly [49]. It is very similar to PRP; however, there are no researches in human 
use compared to all the hemoderivates in dry eye.
7. The methods of obtaining platelet-rich plasma
The two main methods of obtaining platelets are by autologous donation and by the technique 
of platelet apheresis. The advantage of the apheresis technique is that the platelet concentration 
is higher in the final concentrate and should contain at least 5.5 × 10 10 platelets, while its dis-
advantage is the cost that is extremely superior to the autologous total donation technique [48].
In the apheresis technique for platelet collection, Rezende et al. used the Haemonetics 
MCS + 9000 automatic cell separator and the 995-E apheresis-specific kit (Haemonetics Corp.). 
In that system, by means of a venipuncture, the blood of the patient himself is drained to a 
separation device. An optical refraction analyzer separates the platelet layer, and the remaining 
blood is completely returned to the patient, determining the end of a cycle. Sodium citrate can 
be used as an anticoagulant in the ratio of 1 to every 9 ml of whole blood processed. In 2 cycles, 
72 ml of platelet concentrate was collected; the hematimetric indices of the patient and also the 
platelet concentrate indices are evaluated before and after the procedure (Coulter AcT Diff) [81].
Figure 5. Before and after treatment with PRP in patient with diabetic dry eye.
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Platelet growth factors were generally obtained in a ranked room; hence, the handling of 
platelet concentrate was performed within a Category II-Type A biological safety cabinet. 
Then, 2800 microliters of 10% calcium chloride was added, and the final product was main-
tained at +37°C for approximately 30 min. Subsequently, the unit was subjected to centrifu-
gation (900G), and the supernatant serum, which contained the platelet growth factors, was 
transferred to four 50 ml falcon-type tubes (Becton-Dickinson) and maintained at −80°C 
(Revco). Research of bacteria, aerobic and anaerobic, and fungal agents was performed in a 
systematic way.
The release of serum with platelet growth factors in the study by Rezende et al. was done as 
follows: weekly, thawed Falcon tube containing approximately 10 ml of autologous serum 
with platelet growth factors that was transferred to flasks, and the patient is advised to keep 
the biological medicine at a temperature below −10°C (freezer) and to unfreeze it naturally 
immediately before each use [81].
Alio et al. used the autologous donation technique to obtain platelets, when patients were 
submitted to venipuncture and 80–100 ml of blood were collected in sterile 10 ml tubes con-
taining 1 ml of sodium citrate to avoid coagulation. These tubes were left at room temperature 
for 10 min, and only the supernatant (upper tube fraction) was collected as the final product. 
The platelet concentrate was then prepared under sterile conditions in a laminar flow room. 
Two to three milliliters of this concentrate was then placed in sterile eyedrops. The eyedrops 
were kept at −20°C, and only when the patient was going to use an eyedrop bottle, thaw it and 
then keep it at +4°C, discarding that bottle at the end of a week, when a new one is thawed. 
The patients were advised to use these eyedrops four times a day for 1 month [88].
Both methods require the patient to perform an autologous blood donation. Autologous blood 
does not transmit disease; there is no occurrence of hemolytic (alloimmunization), allergic, 
immunological (immunomodulation), or acute lung injury by transfusion and common com-
plications in heterologous donations [91].
The contraindications for autologous donations are anemia or other types of pathological 
hemodilution; conditions that lead to oxygen saturation and hemoglobin saturation (less than 
11 mg/dl); hepatopathies; nephropathies; coagulopathies; hemoglobinopathies; decompen-
sated heart diseases; and presence of infectious diseases such as Chagas, syphilis, HIV, HTLV, 
hepatitis B and C, and others transmissible by blood considered as “relative” contraindications, 
since the patient will receive the same, but there may be contamination of the health team in the 
handling of that blood. In HIV, there may be reactivation of the virus when reinfused [91, 92].
Complications of autologous donation are those inherent to a donor, such as hypotension, 
anemia, angina, and contamination of the material of the blood bags [91].
8. Conclusions
It can be concluded from these studies that the therapeutic response with PRP was actu-
ally satisfactory in severe or moderate dry eye cases which do not respond to conventional 
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therapy. However, randomized clinical trials are needed so that standardized protocols for 
the production, storage, and use of this therapy should be created. Prospective studies should 
also be conducted to evaluate these long-term outcomes.
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